Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Tannir, N. M.; Porta, C.; Tomita, Y.; Mekan, S. F.; McHenry, M. B.; Rini, B. I.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results
    Meeting Abstract

    Dizman, N.; Rosenberg, J. E.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Human prostate cancer immune phenotypes after androgen deprivation therapy
    Meeting Abstract

    Dallos, M.; Obradovic, A.; Chowdhury, N.; Bujanda, Z. L.; Aggen, D. H.; Hawley, J.; Rathkopf, D. E.; Drake, C. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A framework for building a clinically relevant risk model
    Meeting Abstract

    Daly, R. M.; Gorenshteyn, D.; Gazit, L.; Sokolowski, S.; Nicholas, K.; Perry, C.; Adams, L.; Baldwin, A.; Holland, J. C.; Zervoudakis, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057
    Meeting Abstract

    De Wit, R.; Kulkarni, G. S.; Uchio, E. M.; Krieger, L. E. M.; Boormans, J. L.; Roumiguié, M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Haanen, J. B. A. G.; Larkin, J. M. G.; Uemura, M.; Pal, S. K.; Gravis, G.; Campbell, M. T.; Penkov, K.; Lee, J. L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)
    Meeting Abstract

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC)
    Meeting Abstract

    Autio, K. A.; Antonarakis, E. S.; Baser, R.; Stein, M. N.; Shevrin, D. H.; Vaishampayan, U. N.; Mayer, T. M.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets
    Meeting Abstract

    Bandini, M.; Pederzoli, F.; Madison, R.; Briganti, A.; Plimack, E. R.; Ross, J. S.; Niegisch, G.; Yu, E. Y.; Bamias, A.; Agarwal, N.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Targeting checkpoint kinases in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors
    Meeting Abstract

    Atiq, M. O.; Chakraborty, G.; Nandakumar, S.; Mazzu, Y. Z.; Stopsack, K. H.; Jehane, L. E.; Yoshikawa, Y.; Khan, N.; Lee, G. S. M.; Kantoff, P. W.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save